에 대한 최신 뉴스 LegalZoom.com (NASDAQ:LZ) 주식

LegalZoom.com

LegalZoom.com Inc is an online provider of services that meet the legal needs of small businesses and consumers in the United States. The company also offers services that include ongoing compliance and tax advice and filings, business licenses, accounting, virtual mailbox and e-signature solutions, trademark filings, and estate plans.

News

Legal

After-Hours Center

Movers

미국 온라인 법률 기술 및 서비스 회사 리걸줌닷컴(NASDAQ:LZ)의 주가는 회사가 CEO 변경을 발표하고 연간 실적 지침을 낮춘 후 화요일 시장 마감후 애프터마켓에서 하락했다.

리걸줌닷컴 주식은 화요일 애프터마켓에서 급락, 어떤 일이?

LegalZoom.com Inc

Lonza Group Ltd

LONZA GROUP AG UNSP/ADR by Lonza Group AG

La-Z-Boy Inc

LIZHAN ENVIRONMENTAL CORP by Lizhan Environmental Corp

Lizhan Environmental Corp

LZG INTERNATIONAL INC by LZG International, Inc.

LZG International Inc

Lifezone Metals Ltd

Spinnaker ETF Series PARABLA INNOVATION ETF

LOCALIZA RENT A CAR S/ADR by Localiza Rent A Car SA

Localiza Rent A Car SA

Trading Halt: Halted at 7:50:00 p.m. ET - Trading Halt: Halt News Pending

BJDX

SMST

LIFW

SMCX

LIFWW

Numinus Wellness Inc. (OTCQX:<a class="ticker" href="https://www.benzinga.com/stock/NUMIF#OTCQX">NUMIF</a>), a leader in <a href="https://www.benzinga.com/topic/psychedelic-assisted-therapies">psychedelic-assisted mental health care</a>, has <a href="https://www.investors.numinus.com/news/news-details/2024/Numinus-Wellness-Announces-Sale-of-Clinics-and-Unique-Data-Partnership-to-Increase-Access-to-Mental-Health-Care/default.aspx">announced</a> a definitive agreement with Stella, an interventional psychiatry practice, to sell its five wellness clinics in Utah for a total of $3.53 million. The transaction, expected to close by November 30, marks a strategic shift for Numinus, as it pivots towards <a href="https://www.benzinga.com/markets/cannabis/24/09/40845569/mdma-therapy-for-ptsd-faces-fda-delay-are-there-other-ways-forward">developing technology-driven solutions</a> aimed at enhancing the efficiency of mental health care providers.
<h3 class="wp-block-heading">Tech Partnership To Redefine Mental Health Clinics</h3>
In addition to the sale, Numinus and Stella will collaborate on a data-sharing initiative to launch an innovative clinic management platform. By leveraging operational insights from Stella's 12 clinics, Numinus plans to develop a software solution designed to streamline clinic operations, enhance patient outcomes and support insurance reimbursement processes.
"This transaction marks an exciting new chapter in Numinus' strategy to reshape behavioral health care," said Payton Nyquvest, founder and CEO of Numinus. "Leveraging our expertise in patient care, we're now accelerating our mission by focusing on cutting-edge technology solutions. Through our partnership with Stella, we gain unprecedented access to operational data that will enable us to develop a SaaS (software as a service) solution to redefine how clinics operate."
<h3 class="wp-block-heading">Stella Takes Over Utah Operations</h3>
Stella, known for its focus on treating PTSD, anxiety and depression through biological modalities, will assume control of Numinus' Utah clinics. The acquisition includes an upfront payment of $2.08 million, followed by $750,000 in installments throughout 2025, and up to $700,000 in deferred compensation.
"Stella's expansion into Utah brings additional life-changing treatments to the community while supporting Numinus' broader tech initiatives," stated Michael Gershenzon, co-founder and CEO of Stella. "This partnership reflects our commitment to improving behavioral health systems and processes, ultimately enhancing patient care."
<h3 class="wp-block-heading">An Asset-Light Business Model With Enhanced Focus</h3>
With the sale of its clinics, Numinus will shift towards an asset-light model, focusing on its business units like Cedar Clinical Research and the Numinus Network. The strategy aims to integrate clinical research, practitioner training and technology solutions, supporting mental health providers worldwide. The move is part of a broader effort to ease the operational burdens faced by healthcare professionals, particularly as demand for treatments like <a href="https://www.benzinga.com/topic/ketamine-therapy">ketamine</a> and Spravato continues to rise.
"Stella will bolster our clinical solutions offering, leveraging their deep expertise in patient care," Nyquvest added. "We expect strong demand for our Numinus Network Solutions as mental health practitioners navigate growing requests for care."
Cover image made with AI

Cannabis

Psychedelics

NUMIF

Numinus Wellness Sells US Clinics, Partners With Stella For Tech-Driven Mental Health Solutions

President-elect Donald Trump has chosen former Representative Doug Collins (R-GA) to lead the <a href="https://www.benzinga.com/cannabis">U.S. Department of Veterans Affairs (VA). </a>
The decision has sparked discussions about how the agency might handle medical cannabis issues, given his inconsistent track record on the issue, as <a href="https://www.marijuanamoment.net/trumps-pick-to-lead-va-voted-against-letting-agency-doctors-recommend-medical-marijuana-to-veterans-before-he-adopted-a-pro-reform-position/">reported</a> Marijuana Moment.
<h3 class="wp-block-heading">Collins' Record On Cannabis</h3>
During his time in Congress, Collins opposed efforts to expand access to medical cannabis for veterans. Between 2014 and 2016, he voted against three proposals that would have allowed VA doctors to recommend cannabis to their patients.
See Also: <a href="https://www.benzinga.com/markets/cannabis/24/11/42018478/trumps-cabinet-choices-will-his-administration-support-or-restrict-cannabis">Trump&#8217;s Cabinet Choices: Will His Administration Support Or Restrict Cannabis?</a>
Collins' views began to shift in 2019. He supported the STATES Act, which would protect state marijuana programs from federal interference, and co-signed a letter with Rep. Matt Gaetz (R-FL), urging Congress to take action on cannabis policy. 
"We believe this Committee and this Congress must act to clarify the rights and responsibilities, relative to cannabis, of individuals, physicians, businesses, medical patients, and law enforcement officials," they wrote.
Later that year, Collins backed a bipartisan bill to protect banks that serve marijuana businesses in states where it is legal. However, he did not take part in a 2020 vote on federal cannabis legalization.
<h3 class="wp-block-heading">Collins' Stance On Psychedelics</h3>
When it comes to psychedelics, there isn't much known about Collins's stance. However, his shifting views on cannabis policy hint that he could be open to exploring different approaches.
<h3 class="wp-block-heading">Cannabis At The VA</h3>
VA policy has long prohibited its doctors from recommending cannabis, citing marijuana's classification as a Schedule I controlled substance under federal law. This stance has remained consistent across both Republican and Democratic administrations, despite growing support for change in Congress.
Recent efforts to address this issue include a Senate Appropriations Committee request for the VA to explore cannabis as an alternative to opioids. Lawmakers have also introduced measures that would allow VA doctors to recommend cannabis in states where it is legal. These efforts have gained bipartisan support, but none have yet become law.
Veterans service organizations have pushed for further reforms, including expanded research into the potential benefits of cannabis. Last year, a Senate committee approved a bill to study cannabis for veterans with certain medical conditions, but it failed to advance to a floor vote.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/general/health-care/24/11/42017583/trumps-go-wild-on-health-plan-puts-rfk-jr-in-charge-what-it-means-for-cannabis-and-psychedelics-reform">Trump&#8217;s &#8216;Go Wild On Health&#8217; Plan Puts RFK Jr. In Charge: What It Means For Cannabis And Psychedelics Reform</a></li>
</ul>
Cover image made with AI.

Government

Politics

Markets

Trump-Appointed Doug Collins To Lead VA: What's Next For Cannabis and Psychedelics In Veterans' Healthcare?

Chardan Capital analyst Daniil Gataulin maintains Clearside Biomedical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CLSD#NASDAQ">CLSD</a>) with a Buy and maintains $6 price target.

Price Target

Analyst Ratings

CLSD

Chardan Capital Maintains Buy on Clearside Biomedical, Maintains $6 Price Target

Chardan Capital analyst Daniil Gataulin maintains Cognition Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CGTX#NASDAQ">CGTX</a>) with a Buy and maintains $11 price target.

CGTX

Chardan Capital Maintains Buy on Cognition Therapeutics, Maintains $11 Price Target

Telsey Advisory Group analyst Cristina Fernandez maintains Williams-Sonoma (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WSM#NYSE">WSM</a>) with a Outperform and maintains $165 price target.

Telsey Advisory Group Maintains Outperform on Williams-Sonoma, Maintains $165 Price Target

– Approval based on positive data from the AUGMENT-101 clinical trial, in which Revuforj delivered robust and durable rates of remission in R/R acute leukemia patients with a KMT2A translocation –
– Syndax to host conference call today at 6:00 p.m. ET –
WALTHAM, Mass., Nov. 15, 2024 /PRNewswire/ -- Syndax Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SNDX#NASDAQ">SNDX</a>) today announced that the U.S. Food and Drug Administration (FDA) has approved Revuforj&#xAE; (revumenib) as the first and only menin inhibitor for the treatment of relapsed or refractory (R/R) acute leukemia with a lysine methyltransferase 2A gene (KMT2A) translocation in adult and pediatric patients one year and older. The FDA previously granted Breakthrough Therapy and Fast Track designations as well as Priority Review for Revuforj. The New Drug Application (NDA) received approval through the FDA's Real Time Oncology Review (RTOR) program.

Biotech

General

SNDX

Syndax Announces FDA Approval Of Revuforj, The First And Only Menin Inhibitor To Treat Adult And Pediatric Patients With Relapsed Or Refractory Acute Leukemia With A KMT2A Translocation

IT Tech Packaging (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/ITP#AMEX">ITP</a>) reported quarterly losses of $(0.20) per share. This is unchanged from the same period last year. The company reported $25.08 million in sales this quarter. This is a 59.03 percent increase over sales of $15.77 million the same period last year.

Earnings

IT Tech Packaging Q3 EPS $(0.20), Same YoY, Sales $25.08M Up From $15.77M YoY

RumbleOn, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RMBL#NASDAQ">RMBL</a>) (the "Company" or "RumbleOn") announced today that the close of business (4:00 p.m. Central Time) on November 25, 2024 has been fixed as the record date (the "Record Date") for its previously announced proposed $10.0 million registered equity rights offering (the "Rights Offering"), which was announced in a Form 8-K filed with the U.S. Securities and Exchange Commission ("SEC") on November 12, 2024.

Offerings

RMBL

RumbleOn Announces That The Close Of Business On November 25, 2024 Has Been Fixed As The Record Date For Its Previously Announced Proposed $10M Registered Equity Rights Offering

Telsey Advisory Group analyst Dana Telsey maintains European Wax Center (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EWCZ#NASDAQ">EWCZ</a>) with a Outperform and maintains $8 price target.

EWCZ

Telsey Advisory Group Maintains Outperform on European Wax Center, Maintains $8 Price Target

<a href="https://www.spglobal.com/spdji/en/documents/indexnews/announcements/20241115-1475367/1475367_4rcm.pdf" title="https://www.spglobal.com/spdji/en/documents/indexnews/announcements/20241115-1475367/1475367_4rcm.pdf">https://www.spglobal.com/spdji/en/documents/indexnews/announcements/20241115-1475367/1475367_4rcm.pdf</a>

FOUR

Shift4 Payments Will Replace R1 RCM In The S&P Midcap 400 Effective Prior To The Opening Of Trading On Wednesday, November 20

China Green Agriculture, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CGA#NYSE">CGA</a>) has changed its name to Enlightify Inc., effective November 25, 2024. Its ticker symbol will change to ENFY effective November 25, 2024, and it is expected to begin trading under that symbol on November 26, 2024. The Company mainly produces and distributes humic acid-based compound fertilizers, other varieties of compound fertilizers and agricultural products through its subsidiaries in China.

China Green Agriculture Changes Name to Enlightify Inc.; Its Ticker Symbol Will Change To 'ENFY' Effective November 25, 2024, And It Is Expected To Begin Trading Under That Symbol On November 26, 2024

Alpha Cognition (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ACOG#NASDAQ">ACOG</a>) reported quarterly losses of $(0.31) per share. This is a 63.1 percent increase over losses of $(0.84) per share from the same period last year.

ACOG

Alpha Cognition Q2 EPS $(0.31) Up From $(0.84) YoY

D. Boral Capital analyst Jason Kolbert maintains NRX Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NRXP#NASDAQ">NRXP</a>) with a Buy and maintains $31 price target.

NRXP

D. Boral Capital Maintains Buy on NRX Pharmaceuticals, Maintains $31 Price Target

D. Boral Capital analyst Jason Kolbert maintains VolitionRX (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/VNRX#AMEX">VNRX</a>) with a Buy and maintains $5 price target.

VNRX

D. Boral Capital Maintains Buy on VolitionRX, Maintains $5 Price Target

JMP Securities analyst Andrew Boone maintained a Hold rating on LegalZoom (LZ – Research Report) today. The company's shares closed yesterday at $6...

LegalZoom (LZ) Receives a Hold from JMP Securities

Check out this evening's top movers from around Wall Street, compiled by The Fly.&nbsp;&nbsp; HIGHER AFTER EARNINGS – AppLovin (APP)&nbsp;up 28.6% ...

Closing Bell Movers: AppLoving up 29% after Q3 earnings beat

LegalZoom.com, Inc. (LZ) Q3 2024 Earnings Call Transcript

In a report released today, Stephen Sheldon from William Blair reiterated a Hold rating on LegalZoom (LZ – Research Report). The company's shares c...

William Blair Sticks to Their Hold Rating for LegalZoom (LZ)

Analyst Mike McGovern of Bank of America Securities reiterated a Sell rating on LegalZoom (LZ – Research Report), with a price target of $7.20. Mik...

LegalZoom Sell Rating: Concerns Over Revenue Decline, Market Competition, and Growth Sustainability

JPMorgan analyst Ella Smith downgraded LegalZoom (LZ) to Underweight from Neutral with an $8 price target following the Q3 report. LegalZoom's busi...

LegalZoom downgraded to Underweight from Neutral at JPMorgan

Barclays analyst Trevor Young maintained a Hold rating on LegalZoom (LZ – Research Report) today and set a price target of $7.00. The company's sha...

LegalZoom (LZ) Receives a Hold from Barclays

LegalZoom falls as J.P. Morgan moves to Underweight eyeing headwinds in 2025/26

Barclays raised the firm's price target on LegalZoom (LZ) to $8 from $7 and keeps an Equal Weight rating on the shares. The firm increased estimate...

LegalZoom price target raised to $8 from $7 at Barclays

JMP Securities analyst Andrew Boone maintained a Hold rating on LegalZoom (LZ – Research Report) today. The company's shares closed yesterday at $7...

JMP Securities Reaffirms Their Hold Rating on LegalZoom (LZ)

ACLS

ASPN

BROS

CPRX

CTVA

DUOL

FRSH

GILD

HUBS

MELI

MKSI

MTCH

QCOM

RRGB

RXRX

SEDG

SRPT

TNDM

TRIP

TTWO

WOLF

Press Releases

Bragar Eagel & Squire, P.C. Is Investigating Metagenomi, Target Hospitality, Helios, and LegalZoom and Encourages Investors to Contact the Firm

LegalZoom.com (LZ) Closes Down 25%, Faces Investor Scrutiny Over Abrupt CEO Departure – Hagens Berman

Kaskela Law LLC Announces Shareholder Investigation of LegalZoom.com, Inc. (NASDAQ: LZ) and Encourages Investors to Contact the Firm

Bragar Eagel & Squire, P.C. Is Investigating Paragon 28, LegalZoom, and Elastic and Encourages Investors to Contact the Firm

LegalZoom Encourages Couples to Consider Prenuptial Agreements as a Financial Planning Solution

Moore Law, PLLC Encourages LegalZoom.com, Inc. Investors to Contact Law Firm

LegalZoom Gives Away $6 Million in Cash and Products to Over 18,000 Small Businesses through its "Fast Break for Small Business" Grant Program

LegalZoom to Announce Third Quarter 2024 Financial Results on Wednesday, November 6, 2024

Inc. Names LegalZoom as a 2024 Power Partner Award Winner

Johnson Fistel has Commenced an Investigation on Behalf of LegalZoom (LZ) Shareholders

ESTC

HLIO

Amentum Holdings

Booz Allen Hamilton Holding Corporation Common Stock

Booz Allen Hamilton

CACI International, Inc. Class A Common Stock

CACI International

CBIZ

Clarivate

CRA Intl

Dun & Bradstreet Holdings, Inc. Common Stock

Dun & Bradstreet Hldgs

Equifax

Exponent

FTI Consulting

Huron Consulting Group Inc. - Common Stock

Huron Consulting Gr

ICF International

Innodata

Jacobs Solutions

Leidos Holdings

NV5 Global

Planet Labs

Parsons

RELX PLC PLC American Depositary Shares (Each representing One Ordinary Share)

RELX

Science Applications International Corporation - Common Stock

Science Applications Intl

TransUnion

UL Solutions

Verisk Analytics

Willdan Group

Barclays

JP Morgan

Jefferies

B of A Securities

Morgan Stanley

미국 온라인 법률 기술 및 서비스 회사 리걸줌닷컴(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LZ#NASDAQ">LZ</a>)의 주가는 회사가 CEO 변경을 발표하고 <a href="https://www.benzinga.com/pressreleases/24/07/g39698861/legalzoom-announces-leadership-transition" target="_blank" rel="noopener" data-google-interstitial="false">연간 실적 지침을 낮춘</a> 후 화요일 시장 마감후 애프터마켓에서 하락했다.
발표 내용 (The Details): 리걸줌은 현 CEO 댄 웨르니코프(Dan Wernikoff)가 사임하고 이사회에서도 사임한다고 발표했다. 이 회사는 이사회 의장인 제프리 스티벨(Jeffrey Stibel)이 즉시 발효되는 리걸줌의 차기 CEO로 임명되었다고 밝혔다.
스티벨은 "우리의 놀라운 팀과 함께 510억 달러 규모의 서비스 가능 시장에서 이 새로운 도전에 착수하게 되어 매우 기쁘다"고 말했다.
&#8220;우리의 선도적인 브랜드 위치와 비즈니스를 구독 수익으로 전환하는 과정을 고려할 때 리걸줌은 중소기업들과 소비자들에게 서비스를 제공하는 데 초점을 맞춘 법률 및 규정 준수 서비스 업계를 뒤흔들 수 있는 좋은 위치에 있다고 믿고 있다.&#8221;
리걸줌은 또한 연간 매출 지침을 6억 7,500만 ~ 6억 8,500만 달러 범위로 줄였다. 이는 추정치 7억 1,035만 3천 달러와 비교되며, 연간 잉여 현금 흐름 기대치는 7,500만 ~ 8,500만 달러 범위이다.
이 회사는 2분기 매출 지침을 1억 7,200만 달러에서 1억 7,600만 달러 범위로 재확인하고 EBITDA를 2,500만 달러에서 2,700만 달러 범위로 조정했다.
LZ 주가 움직임: <a href="https://pro.benzinga.com/?gspk=YWRhbWVja2VydDUzMzY&amp;gsxid=zBMR4PKmcgBw">벤징가 프로</a>에 따르면 리걸줌의 주식은 화요일 시장 마감 후 시간외 거래에서 11.08% 떨어진 6.98달러에 거래되었다.
이미지: Mediamodifier
Benzinga Pro의 독점 뉴스 및 도구로 더 많은 승리를 거두세요 
독점 속보 및 스캐너와 같은 Benzinga Pro의 강력한 도구 세트로 다른 트레이더보다 우위를 점하세요. 
<a href="https://www.benzinga.com/pro/register?t=be2bewe5mibe3bz3&amp;utm_source=bz-kor" target="_blank" rel="noreferrer noopener">여기를 클릭</a>하여 14일 무료 체험을 시작하세요.

Comments

LegalZoom.com

뉴스

에 대한 최신 뉴스 LegalZoom.com (NASDAQ:LZ) 주식

화요일, 7월 09, 2024

사람들이 또한 지켜본다

뉴스

파트너 / 기고자

벤징가 글로벌